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Several KPIs were examined, but the study focuses on the mean pharmaceutical 
cost per patient, which was then adjusted to the case mix of the units, by using a 
hospital clinical weight indicator, estimated as the weighted average of particular 
incidents, based on GR-DRG data. The results were statistically analysed, in order 
to group the changes, before and after the indicator’s adjustment, per hospital size 
category and assess hospitals’ relative ranking. Results: The results reveal that 
there was a significant -but diminishing as the bed number increases- rise in the 
mean pharmaceutical cost per patient for three categories (25.49%, 14.23%, 11.74% 
increase for hospitals with less than 100, 101-250 and 251-400 beds, respectively) 
after the indicator was adjusted to the hospitals’ clinical workload. For hospitals 
with more than 400 beds, the mean pharmaceutical cost per patient decreased 
by 15.38%, after the adjustment. The results also indicate significant changes in 
hospital ranking, even within the 4 categories, ranging from a 34 places ranking 
rise for Onassis Cardiac Surgery Centre, to a 21 places ranking drop for the G.H. of 
Thessaloniki ‘Agios Dimitrios’. ConClusions: Hospitals with more severe than 
average incidents, (cancer hospitals, cardiac surgery centres, etc) improved their 
performance and relative ranking, while small health centres and regional hospi-
tals reported worse results after the indicators’ adjustment. The study concludes 
that clinical workload should be incorporated in hospitals’ pharmaceutical cost 
assessment.
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objeCtives: The objective of this work is to set a cost benefit analysis of the use 
of fibrin sealant patch as supportive treatment in surgery for improvement of 
hemostasis, to promote tissue sealing and for suture support in surgery in those 
cases where standard techniques are not adequate. Methods: Efficacy data were 
obtained from a systematic literature review. The analysis of the costs of hospitali-
zation was conducted on the basis of detection of actual costs, observed from the 
point of view of the hospital. We performed a cost benefit analysis of the use of fibrin 
sealant patch valuing the hospitalization and the consequent use of resources. The 
results of the economic evaluation were subjected to sensitivity analysis, building a 
stochastic simulation with 1000 repetitions within a normal distribution. Results: 
In the group of patients treated with fibrin sealant patch it was observed the 
decrease of the duration of hospitalization vs. the group of patients treated with 
standard techniques: on average 2.66 days, within a range between 0.55 and 11.80 
days. The cost per day of hospitalization was estimated at Euro 206.00: this led to 
a saving in terms of lower costs for the hospital, quantifiable in 549 Euro, from a 
minimum of 103 Euro and a maximum of 2431 Euro. The use of fibrin sealant patch 
led then an average savings of about 304.00 Euro per patient with a cost-benefit ratio 
equal to 2.24 (min. 00.42 - max. 9.93). Overall the results of the sensitivity statistics 
confirm a lower length of stay associated with fibrin sealant patch than standard 
care. ConClusions: The analysis shows the positive role of fibrin sealant patch 
as supportive treatment in surgery where standard techniques are revealed not 
adequate, with decreased postoperative complications, shorter hospital stays and 
reducing hospital costs.
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objeCtives: Personalized medicine (PM) consists of a customized approach consid-
ering individual biological and genetic characteristics to prevent, diagnose or treat 
a medical condition. Although health benefits of PM have been demonstrated, its 
economic impact is not established. The aim of this review was to explore its cost-
effectiveness and summarize the key parameters in every therapeutically health 
areas. Methods: A systematic review of economic evaluations was performed 
using the PICO method. Population consisted of patients who might benefit from 
PM; intervention and comparators were PM and usual care and outcomes were 
results of economic evaluations. The literature search was performed with the NHS 
EED filters using Medline, Embase and Pubmed from 2004 to 2014. Eligible articles 
were economic evaluations, with preventive, diagnostic or therapeutic interven-
tions in PM. Results: A total of 76,488 studies were identified and 213 met the 
inclusion criteria. Cost-utility studies were the most frequent (60.1%), followed 
by cost-effectiveness studies (32.1%) with a healthcare-payer perspective (67.9%). 
Time horizon varied between 28 days and lifetime. Cancer was the most evaluated 
therapeutic field (46.9%) followed by cardiovascular diseases (19.2%) and neurologic 
and psychological diseases (10.3%). A total of 39.9% of the studies were conducted 
in the United States. Adjusted 2015USD ICERs varied from dominant to $9,780759 
per quality adjusted life year (QALY). Among these, 44% have an ICER of $50,000/
QALY or less, while 57% have an ICER of $100,000/QALY or less. Overall, a total of 
147 studies compared their ICER to the reference threshold established by their 
country. Among the ICERs presented, 60.2% were reported as cost-effective (15.3% 
were dominant) and 39.8% non cost-effective. ConClusions: Despite a high het-
erogeneity among the studies, most of them suggest that personalized medicine 
could be cost-effective.
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for the delay in indexing of publications, we included all studies with a publica-
tion date of 2014 that were indexed in PubMed up to 1 June 2015. Results: The 
search identified 1,870 articles published in 2014. Of these, 975 met the inclusion 
criteria and were subcategorised according to topic. The greatest number, 13%, 
were conducted in patients with cardiovascular diseases, with 11% in musculo-
skeletal disorders, 10% each in cancer and digestive disorders, 8% in mental health 
disorders, 7% each in infective disease or acute care, and 6% each in respiratory, 
endocrine and urogenital disorders, and in general populations or healthcare set-
tings. All other disease areas were relatively underrepresented, accounting for 2% 
or fewer of the relevant publications. ConClusions: Despite product pipelines 
being weighted towards new cancer drugs and the challenges in demonstrating 
their cost-effectiveness, cancers are relatively under-represented in recent stud-
ies assessing economic burden. The reasons why costs may be less important an 
outcome in cancer than in cardiovascular or musculoskeletal diseases are unclear, 
but may reflect a more established, often generic or surgical, therapeutic portfolio.
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objeCtives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. Methods: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 
per QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the 
maximum accepted thresholds for end of life care therapies. ConClusions: 
Review of cost effectiveness studies for ultra orphan therapies shows that none 
were able to show ICERs within typical thresholds. These results suggest a need 
for new policy regarding acceptable threshold, or type of models for assessing the 
cost effectiveness of ultra orphan therapies.
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objeCtives: As in most European countries, spending on pharmaceuticals has 
also been cut in recent years in Italy through a series of measures, including price 
reduction and boosting of off-patent drugs prescription. Laws 338/2000 and 405/2001 
incentivised the use of generic drugs and introduced patients’ co-payment if they 
preferred a branded vs off-patent drug. The aim of this study was to analyse the 
consumption and expenditure trend for off-patent drugs in Italy since the intro-
duction of these new measures. Methods: Off-patent (branded and unbranded) 
drug consumption and expenditure indicators from 2004 (first year in which net 
expenditure was available) to 2013 (last available year) were analysed from the 
Observatory on the Use of Medicines (OSMED) published reports. Results: In 2004 
consumption by defined daily dose (DDD) per 1,000 habitants was 166.8 (21.7% on 
total DDD), while in 2013, it was 663.0 (64.3% on total DDD) for territorial drugs. 
Per-capita expenditure was € 22 (10.1% of net territorial expenditures) in 2004 and 
€ 62.4 in 2013 (41.5% of net territorial expenditure). Such results were mainly due 
to the higher number of off-patent drugs available on the market and not only to 
increased use of generic drugs. In 2004, the percentage of unbranded drugs was 
1.9% and raised until 14.9% in 2013. Despite such growth, Italy was in 2013 the 
third European country (behind Greece and Ireland) for expenditure on branded 
drugs, with a very low uptake vs Germany, France, Spain and UK showing an inci-
dence of generic territorial drug expenditure between 30 and 40%. ConClusions: 
Consumption and expenditure on off-patent drugs has increased in the last 10 years 
in Italy, however the unbranded drugs uptake is still very low when compared with 
other European countries.
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objeCtives: To examine how hospitals’ pharmaceutical cost changes when clinical 
workload indicators are incorporated in the measurement and provide corrective 
estimates to the comparative performance assessment of the MoH for Greek NHS 
hospitals, for 2013. Methods: The study includes annual detailed financial and 
operational data, as recorded by the MoH’s BI system, ESY.net, and analytical data 
on the type of incidents (based on GR-DRGs) recorded, for 129 Greek NHS hospitals. 
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objeCtives: The financial basis of sick pay is provided by health insurance premi-
ums paid by employers and employees in Hungary. Due to the economic crisis in 
2007, the number of people employed significantly decreased. The aim of our study 
was to analyse the changes of nationwide sick-pay expenditures of the National 
Health Insurance Fund Administration of Hungary. Methods: We used the data of 
National Health Insurance Fund Administration of Hungary and statistical reports 
of Nr. OSAP 1514, as well as data of Hungarian Central Statistical Office from the 
years of 2005-2013. We analysed the following indicators: average daily sick-pay 
expenditure and the nationwide sick-pay expenditures National Health Insurance 
Fund Administration, and the number of days spent on sick-leave. Results: In 
the investigated period the expenditure for one day of sick-pay gradually increased 
between the years of 2005 and 2009, from 2420 to 3101 Hungarian Forint (HUF). This 
is closely correlated with the changes of the average general wages. The general 
daily amount of sick-pay between 2010-2012 stagnated on 2700 HUF, then increased 
to 2929 HUF in 2013. Sick-pay expenditure of the National Health Insurance Fund 
Administration was around 100 billion HUF between 2005-2008, in 2009 it reached 
108 billion HUF. Tthen due to governmental actions after the economic crisis it fell 
by 26% in 2010 (79 billion HUF), with further decline to 57 billion HUF in 2012 and 60 
in 2013. In the investigated period the number of days spent on sick-leave decreased 
from 37.4 million to 19.8 million. ConClusions: We can conclude that the amount 
spent on sick-pay paid by the National Health Insurance Fund in Hungary between 
2005 and 2013 significantly decreased. Thus the sick-pay expenditures were strongly 
influenced by the economic crisis.
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objeCtives: High rates of preterm birth and limited access to evidence-based, 
cost-effective interventions unsupported by fragmented and unsystematic financ-
ing hinder child mortality reduction locally. We aimed to cost a full spectrum of 
care for prematurity complications, to develop a comprehensive benefit pack-
age to ensure financial risk protection through the National Health Insurance 
Program. Methods: Two frameworks of standard care algorithms and outcomes 
were developed in two birthweight categories (500-< 1,500g; 1500-< 2500g) and for 
women at < 37 weeks using literature- and expert-panel-based data. Valuation of 
cost components was done. Gross costing was used for accommodation-related 
costs, where general service components were aggregated; modified microcosting 
for clinical-related costs, with patient and hospital specific costs identified; and 
modified bottom-up approach for patient-specific unit costs per service. Component 
costs from 11 hospitals and 3 maternity clinics surveyed nationwide were entered 
into a configured spreadsheet. Results: 17 Diagnosis-Related Groups (DRGs) were 
formed, subdivided into antenatal (e.g., antenatal steroids, maternal transfer), inpa-
tient (e.g. NICU, Kangaroo Mother Care) and pre-discharge care (e.g. screening, vac-
cinations, counseling), with calculated unit costs and DRG weights for each. The 
lowest cost inpatient package was for the birthweight 1500 - 2499g with minor 
complications subgroup - approximately 32.4% of all preterms. The highest cost 
was for ~5.1% of all preterms, birthweight 500 - < 1500g requiring intensive care 
for major complications then Kangaroo Mother Care. ConClusions: Algorithms 
of standard care and outcomes for two birthweight categories and itemized cost 
modeling were used for prospective evaluation of costs. Results of the costing exer-
cise of 17 DRGs will inform actuarial analyses, for final decision on the eventual 
package design spanning primary to “catastrophic” care for premature newborns. 
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objeCtives: To develop a method of setting a Drug Price Reference Index (DPRI) 
in the Philippines to ensure good value for money in the procurement and reim-
bursement of essential medicines. Methods: A database of prevailing drug pro-
curement prices was created from actual purchase orders submitted in 2013 by 
government procuring entities in the Philippines. The database includes informa-
tion on the unit cost, volumes of procurement, source/supplier/manufacturer, 
brand, mode of procurement and location of the hospital for each formulation 
and strength of all drugs in the National Formulary. Multivariate regression analy-
ses were performed for commonly sourced essential drugs exploring possible 
determinants of drug costs, which include quantities procured and hospital bed 
capacity. Further cost-comparisons were made for other potential determinants 
such as mode of procurement, supplier/manufacturer and distance of distribu-
tion. Results: Price data was analyzed for 20 drug products with the highest 
share of procurement in terms of volume and value. Extreme wide variations 
in unit costs were consistently observed for all drugs analyzed. The price dif-
ferentials, i.e. high/low ratio, was found to be up to 60 times when comparing 
the highest to the lowest priced drugs. The variations in prices were not associ-
ated by volumes procured, distance of distribution and hospital bed capacity. 
objeCtives: Pharmaceutical companies have been able to submit information 
related to pharmacoeconomics as a reference material when applying for National 
Health Insurance drug price listing under current Japanese system. The purpose of 
this study is to investigate a role of pharmacoeconomic analysis in achieving high 
drug pricing in the past. Methods: The status of acquiring premium for drugs 
listed on drug price listing in 10 years from 2004 to 2013 in Japan was studied. 
For drugs acquired premium for usefulness I and premium for innovation with 
further premium expected, papers studied on cost-effectiveness of the drug for 
Japanese patients were searched by Pubmed and Japan Medical Abstracts Society 
database, to investigate the role of pharmacoeconomic analysis in assessing pre-
mium acquisition. Results: There were 9 new drugs which acquired premium 
for usefulness I in 10 years from 2004 to 2013 in Japan. No new drug was granted 
premium for innovation. There were cost-effectiveness studies having the same 
indication on 2 drugs, one each for the drugs (Cinacalcet hydrochloride for second-
ary hyperparathyroidism under maintenance dialysis: premium rate 25% [2007], 
Perflubutane for imaging of hepatic mass lesions in ultrasonography: premium rate 
35% [2006]). No relationship for considering premium rate was observed from each 
paper. ConClusions: Although pharmaceutical companies have been allowed to 
submit pharmacoeconomicanalysis when applying for drug price listing of new drug 
in Japan, it may have not been fully functioned. Pharmaceutical companies would 
have a meaningful discussion on consideration for pharmacoeconomic analysis 
utilization, heading towards introduction of pharmacoeconomic analysis on a trial 
basis starting from the 2016 fiscal year.
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objeCtives: The prices of medicinal products paid by public funds in Bulgaria 
are regulated according to the legislation on the basis of the lowest manufacturer 
price of the same product in seventeen European countries. The Positive Drug List 
includes medicinal products which are paid by the National Health Insurance Fund 
(NHIF), medicinal products paid from the budget of the hospitals and medicinal 
products for treatment of AIDS, infectious diseases, as well as vaccines, specific 
sera, immunoglobulins, paid by the Ministry of health (MH). The goal of the study 
is to determine the influence of external and internal reference pricing as a cost 
containment measure for one year period. Methods: The analysis is made on a 
basis of cost for medicinal products paid by NHIF, MH and hospitals based on the 
reference value of each INN during 2014. We analyzed the changes in reference 
value of INNs. Only the official prices are used, i.e. we did not take into account 
the confidential discounts. Results: In PDL medicinal products are grouped by 
INN and pharmaceutical form and the reference value within the group is set 
on a basis of the cheapest product. The prices of medicinal products included 
in PDL are checked every 6/12 months. For medicines paid by NHIF, the refer-
ence value of 85 INNs is reduced, the reduction ranges from 0.14% to 55.27% and 
total savings are 10,319,703 BGN. 31 INNs in oncology medicines for hospital use 
have reduced reference value and total savings are 9,852,593 BGN. For medicinal 
products paid by MH, 10 INNs have reduced reference value and total savings 
are 2,077,892 BGN. ConClusions: Analysis of changes in the reference values 
of medicinal products indicates that external and internal reference pricing is a 
good basis for saving public funds, but other cost containment measures are also 
needed.
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objeCtives: Rejection of kidney transplants remains a challenging clinical problem. 
Traditional immunosuppression (IS) consisting of CNI and other drugs effectively 
prevent rejection but are nephro-toxic and favor the development of malignancies 
and cardiovascular events and therefore compromise patient outcomes. Biomarker-
driven immunosuppression is an approach currently studied to identify patients 
eligible for reduced IS based on assessing the anti-donor alloimmune response. 
Our objective is to present the health-economic study design incorporated in the 
CELLIMIN study to investigate the impact of a biomarker-stratification panel to 
identify patients eligible for reduced IS. Methods: CELLIMIN is a prospective rand-
omized controlled clinical trial that will randomize 301 patients, eligible for reduced 
IS, on a 1:1 ratio to a “high-IS” and a “low-IS” regime. Comparisons will be made 
between these arms and assumed full IS regimes. In addition to clinical outcomes, 
health economic outcomes will be collected following transplantation. Costs for 
IS medication are likely to decrease. A reduction in adverse events attributable 
to IS might further reduce costs. Additional costs for the stratification process, 
as well as for additional monitoring visits to precisely control blood trough lev-
els of IS medication might increase total costs. Results: Resource consumption 
is assessed alongside the CELLIMIN trial at initial discharge, repeated discharge, 
M12, and M24. We developed health-economic questionnaires for the initial hospi-
talization, repeated hospitalizations and for regular study visits to capture in- and 
outpatient resource consumption. Quality of life will be assessed using disease-
specific (KTQ) and generic questionnaires (SF-36v2 and EQ5D-5L). EQ5D-5L values, 
along with mortality data, will be used to compute quality adjusted life years that 
will inform incremental cost-effectiveness analyses. ConClusions:: Prospective 
inclusion of health-economic endpoints in clinical trials is important to support 
future decision-making by payers and providers. The CELLIMIN study collects tar-
geted information on quality of life and resource utilization to facilitate future 
health-economic analyses.
